Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Cellectar Biosciences
company
About
Cellectar Biosciences is a pharmaceutical research company specializing in cancer drugs.
- 1 - 10
Highlights
Details
- Last Funding Type
- Series Unknown
- Last Funding Money Raised
- $13M
- Industries
- Biotechnology,Medical Device,Therapeutics
- Founded date
- Jan 1, 2002
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Cellectar Biosciences, a radiopharmaceutical company, designs and develops products to detect, treat, and monitor various human cancers. Its products include 131I-CLR1404, a compound for cancer therapy. The company's product candidates combine lipid-like molecules and phospholipid ethers analogs with radioisotopes to image or destroy malignant cells.Cellectar Biosciences was formerly known as Cellectar, LLC and changed its name in 2008. The company was founded in 2003 and is based in Madison, Wisconsin.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$13M
Cellectar Biosciences has raised a total of
$13M
in funding over 2 rounds. Their latest funding was raised on
Jan 8, 2008 from a Series Unknown round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 8, 2008 | Series Unknown | $13M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Cellectar Biosciences is funded by 1 investors.
Advantage Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Advantage Capital
|
— | Series Unknown |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
